Pfizer Inc
showed further weakness in its main business of prescription medicines, sending shares down more than 3 percent on concern over future growth as the company prepares to divest better-performing non-pharmaceuticals businesses.Pfizer Inc reported higher quarterly earnings, as higher sales of animal health and nutritional products that the company aims to divest helped offset falling sales of its core pharmaceuticals business.
Wall Street equity futures were lower on Tuesday as a last-minute congressional deal to raise the U.S. debt ceiling failed to assuage investor concerns that a credit downgrade could be avoided.
Wall Street equity futures were lower on Tuesday as a last-minute congressional deal to raise the U.S. debt ceiling failed to assuage investor concerns that a credit downgrade could be avoided.
Stock index futures pointed to a lower opening on Wall Street on Tuesday, with futures for the S&P 500 down 0.5 percent, Dow Jones futures down 0.2 percent and Nasdaq 100 futures down 0.5 percent at 0919 GMT.
Pfizer Inc
is expected to report lower quarterly earnings on Tuesday, hurt by competition from generic copies of its Lipitor cholesterol fighter, but investors will focus mainly what the company plans to do after Lipitor faces U.S. generics in November.Wall Street fell for a sixth day on Monday on renewed angst about Washington's ability to reach a deal on raising the U.S. debt ceiling and following disappointing news from the manufacturing sector.
Wall Street fell for a sixth day on Monday on renewed angst about Washington's ability to reach a deal on raising the U.S. debt ceiling and following disappointing news from the manufacturing sector.
Stocks fell a sixth day on Monday as weaker-than-expected U.S. manufacturing data and uncertainty over the debt deal in Washington kept the mood skittish on Wall Street.
Merck & Co Inc plans to cut another 12,000 to 13,000 jobs by late 2015 to wring out additional annual cost savings of up to $1.5 billion that can be plowed back into research and deal making.
At least three private equity firms are planning to bid for a clutch of GlaxoSmithKline's non-prescription products, expecting limited competition from rival large pharma groups, people familiar with the process said.
Pharmaceutical giant Pfizer (PFE) is considering selling its animal health and baby food units in hopes of appeasing shareholders' demands.
Researches have found that Chantix, the popular Pfizer drug that helps people quit smoking, may instead give people heart attacks and other cardiovascular problems.
A study showed an increase in the risk of heart attacks and other cardiovascular cases among smokers who take the drug Chantix to help them quit.
Pfizer Inc
may have won over shareholders with its recent decision to pare back research and development spending but could be shortchanging them in the long run, according to its former research chief.A study says Toyota leads global companies in total dollars invested in research and development.
Eli Lilly and Co is committed to spending what it takes to come up with innovative drugs over the long term, its chief executive said, even though the company's earnings are expected to tumble over the next three years.
The top pre-market NASDAQ Stock Market gainers are: Westport Innovations, ICAgen, SIGA Technologies, Spreadtrum Communications, and OmniVision Technologies. The top pre-market NASDAQ Stock Market losers are: Swisher Hygiene, JA Solar Holdings, Logitech International, ASML Holding, and Aixtron.
The top pre-market NASDAQ Stock Market gainers are: Icagen, Pacific Biosciences of California, Sangamo Biosciences, Columbia Laboratories, and Sina. The top pre-market NASDAQ Stock Market losers are: Pain Therapeutics, Logitech International, Zalicus, Partner Communications, and Spreadtrum Communications.
The top pre-market NASDAQ Stock Market gainers are: ASM International, Tibco Software, Comcast, SIRIUS XM Radio, and Sina. The top pre-market NASDAQ Stock Market losers are: Pain Therapeutics, Durect, Micron Technology, Oracle, and Finish Line.
The companies whose shares are moving in pre-market trade on Thursday are: Bristol Myers Squibb, Red Hat, Pfizer, Bed Bath & Beyond, Walgreen, Lennar, Conagra Foods, Nabors Industries, Expedia and Hess Corp.
Stocks rose on Monday, as a move toward a key technical level on the S&P 500 drew support, while the latest plan to help Greece solve its debt woes eased some investor worries.
